Does the media prefer AARD or VALN?

In the previous week, Aardvark Therapeutics and Aardvark Therapeutics both had 1 articles in the media. Valneva's average media sentiment score of 0.91 beat Aardvark Therapeutics' score of 0.59 indicating that Valneva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AARD or SLN?

In the previous week, Aardvark Therapeutics and Aardvark Therapeutics both had 1 articles in the media. Aardvark Therapeutics' average media sentiment score of 0.59 beat Silence Therapeutics' score of -0.72 indicating that Aardvark Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Which has better valuation & earnings, ZURA or AARD?

Zura Bio is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zura Bio N/A N/A -$99.35M -$1.09 N/A Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A

Is ZURA or AARD more profitable?

Zura Bio's return on equity of -55.74% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -55.74% -48.07% Aardvark Therapeutics N/A -61.71% -56.29%

Does the media favor ZURA or AARD?

In the previous week, Zura Bio had 1 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 2 mentions for Zura Bio and 1 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.59 beat Zura Bio's score of -0.11 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aardvark Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AARD or CCCC?

In the previous week, C4 Therapeutics had 1 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 2 mentions for C4 Therapeutics and 1 mentions for Aardvark Therapeutics. C4 Therapeutics' average media sentiment score of 0.89 beat Aardvark Therapeutics' score of 0.59 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive C4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, RZLT or AARD?

Rezolute is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A

Is RZLT or AARD more profitable?

Rezolute's return on equity of -58.82% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Aardvark Therapeutics N/A -61.71% -56.29%

Does the media prefer RZLT or AARD?

In the previous week, Rezolute had 2 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 3 mentions for Rezolute and 1 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.59 beat Rezolute's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aardvark Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aardvark Therapeutics (AARD) Competitors

$5.70 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$5.61 -0.09 (-1.58%)

As of 07/2/2026 07:26 PM Eastern

Compare

AARD vs. VALN, SLN, ZURA, CCCC, and RZLT

Should you buy Aardvark Therapeutics stock or one of its competitors? MarketBeat compares Aardvark Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aardvark Therapeutics include Valneva (VALN), Silence Therapeutics (SLN), Zura Bio (ZURA), C4 Therapeutics (CCCC), and Rezolute (RZLT). These companies are all part of the "pharmaceutical products" industry.

How does Aardvark Therapeutics compare to Valneva?

Aardvark Therapeutics (NASDAQ:AARD) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Aardvark Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Aardvark Therapeutics' return on equity of -61.71% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Valneva	-88.87%	-107.63%	-33.02%

11.4% of Valneva shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aardvark Therapeutics has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Valneva	$197.56M	2.51	-$130.33M	-$1.87	N/A

Aardvark Therapeutics presently has a consensus target price of $19.70, indicating a potential upside of 245.61%. Valneva has a consensus target price of $11.98, indicating a potential upside of 129.41%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Aardvark Therapeutics is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Aardvark Therapeutics and Aardvark Therapeutics both had 1 articles in the media. Valneva's average media sentiment score of 0.91 beat Aardvark Therapeutics' score of 0.59 indicating that Valneva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aardvark Therapeutics has a beta of 3.93, meaning that its share price is 293% more volatile than the broader market. Comparatively, Valneva has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Summary

Aardvark Therapeutics beats Valneva on 9 of the 15 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Silence Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Aardvark Therapeutics has higher earnings, but lower revenue than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Silence Therapeutics	$560K	876.47	-$88.61M	-$1.59	N/A

Aardvark Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Aardvark Therapeutics' return on equity of -61.71% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

Aardvark Therapeutics currently has a consensus price target of $19.70, indicating a potential upside of 245.61%. Silence Therapeutics has a consensus price target of $55.00, indicating a potential upside of 429.36%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Aardvark Therapeutics has a beta of 3.93, meaning that its share price is 293% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

98.7% of Silence Therapeutics shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Aardvark Therapeutics and Aardvark Therapeutics both had 1 articles in the media. Aardvark Therapeutics' average media sentiment score of 0.59 beat Silence Therapeutics' score of -0.72 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Aardvark Therapeutics and Silence Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Zura Bio?

Zura Bio (NASDAQ:ZURA) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

In the previous week, Zura Bio had 1 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 2 mentions for Zura Bio and 1 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.59 beat Zura Bio's score of -0.11 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aardvark Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zura Bio is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

61.1% of Zura Bio shares are owned by institutional investors. 12.4% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zura Bio's return on equity of -55.74% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
Aardvark Therapeutics	N/A	-61.71%	-56.29%

Zura Bio has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.93, meaning that its stock price is 293% more volatile than the broader market.

Zura Bio currently has a consensus price target of $10.75, indicating a potential upside of 107.93%. Aardvark Therapeutics has a consensus price target of $19.70, indicating a potential upside of 245.61%. Given Aardvark Therapeutics' higher possible upside, analysts clearly believe Aardvark Therapeutics is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Summary

Zura Bio beats Aardvark Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Aardvark Therapeutics compare to C4 Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Aardvark Therapeutics has higher earnings, but lower revenue than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
C4 Therapeutics	$35.95M	13.23	-$104.99M	-$1.19	N/A

Aardvark Therapeutics currently has a consensus price target of $19.70, suggesting a potential upside of 245.61%. C4 Therapeutics has a consensus price target of $7.75, suggesting a potential upside of 80.23%. Given Aardvark Therapeutics' higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, C4 Therapeutics had 1 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 2 mentions for C4 Therapeutics and 1 mentions for Aardvark Therapeutics. C4 Therapeutics' average media sentiment score of 0.89 beat Aardvark Therapeutics' score of 0.59 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
C4 Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of C4 Therapeutics shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aardvark Therapeutics has a beta of 3.93, meaning that its share price is 293% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.9, meaning that its share price is 190% more volatile than the broader market.

Aardvark Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. C4 Therapeutics' return on equity of -50.68% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
C4 Therapeutics	-297.76%	-50.68%	-33.22%

Summary

C4 Therapeutics beats Aardvark Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Rezolute?

Rezolute (NASDAQ:RZLT) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Rezolute has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.93, meaning that its stock price is 293% more volatile than the broader market.

Rezolute currently has a consensus price target of $9.38, suggesting a potential upside of 90.94%. Aardvark Therapeutics has a consensus price target of $19.70, suggesting a potential upside of 245.61%. Given Aardvark Therapeutics' higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Rezolute is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

In the previous week, Rezolute had 2 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 3 mentions for Rezolute and 1 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.59 beat Rezolute's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aardvark Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.0% of Rezolute shares are owned by institutional investors. 14.8% of Rezolute shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rezolute's return on equity of -58.82% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Aardvark Therapeutics	N/A	-61.71%	-56.29%

Summary

Rezolute beats Aardvark Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Aardvark Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AARD vs. The Competition

Export

Metric	Aardvark Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$124.74M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-1.78	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	1.16	8.66	10.96	6.46
Net Income	-$57.59M	$23.81M	$3.57B	$337.01M
7 Day Performance	19.00%	3.39%	2.12%	1.69%
1 Month Performance	54.89%	10.81%	5.25%	3.81%
1 Year Performance	-59.05%	62.61%	33.29%	23.90%

Aardvark Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AARD Aardvark Therapeutics	3.9217 of 5 stars	$5.70 flat	$19.70 +245.6%	-59.1%	$124.74M	N/A	N/A	18	Analyst Upgrade Gap Down
VALN Valneva	3.2985 of 5 stars	$5.22 flat	$11.98 +129.4%	-8.7%	$495.78M	$197.56M	N/A	700
SLN Silence Therapeutics	2.4557 of 5 stars	$10.39 flat	$55.00 +429.4%	+87.5%	$490.77M	$560K	N/A	100	Gap Up
ZURA Zura Bio	2.9602 of 5 stars	$5.17 flat	$10.75 +107.9%	+355.1%	$490.53M	N/A	N/A	3	Analyst Forecast
CCCC C4 Therapeutics	1.8384 of 5 stars	$4.30 flat	$7.75 +80.2%	+188.6%	$475.44M	$35.95M	N/A	150	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AARD) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aardvark Therapeutics (AARD) Competitors

AARD vs. VALN, SLN, ZURA, CCCC, and RZLT

How does Aardvark Therapeutics compare to Valneva?

Summary

How does Aardvark Therapeutics compare to Silence Therapeutics?

Summary

How does Aardvark Therapeutics compare to Zura Bio?

Summary

How does Aardvark Therapeutics compare to C4 Therapeutics?

Summary

How does Aardvark Therapeutics compare to Rezolute?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD vs. The Competition

Aardvark Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aardvark Therapeutics (AARD) Competitors

AARD vs. VALN, SLN, ZURA, CCCC, and RZLT

How does Aardvark Therapeutics compare to Valneva?

Is AARD or VALN more profitable?

Do institutionals & insiders have more ownership in AARD or VALN?

Which has preferable valuation and earnings, AARD or VALN?

Do analysts prefer AARD or VALN?

Does the media prefer AARD or VALN?

Which has more risk & volatility, AARD or VALN?

Summary

How does Aardvark Therapeutics compare to Silence Therapeutics?

Which has higher earnings and valuation, AARD or SLN?

Is AARD or SLN more profitable?

Do analysts rate AARD or SLN?

Which has more risk & volatility, AARD or SLN?

Do insiders & institutionals have more ownership in AARD or SLN?

Does the media prefer AARD or SLN?

Summary

How does Aardvark Therapeutics compare to Zura Bio?

Does the media favor ZURA or AARD?

Which has better valuation & earnings, ZURA or AARD?

Do institutionals & insiders have more ownership in ZURA or AARD?

Is ZURA or AARD more profitable?

Which has more volatility and risk, ZURA or AARD?

Do analysts rate ZURA or AARD?

Summary

How does Aardvark Therapeutics compare to C4 Therapeutics?

Which has preferable earnings and valuation, AARD or CCCC?

Do analysts recommend AARD or CCCC?

Does the media prefer AARD or CCCC?

Do insiders & institutionals hold more shares of AARD or CCCC?

Which has more risk & volatility, AARD or CCCC?

Is AARD or CCCC more profitable?

Summary

How does Aardvark Therapeutics compare to Rezolute?

Which has more volatility and risk, RZLT or AARD?

Do analysts recommend RZLT or AARD?

Which has better earnings & valuation, RZLT or AARD?

Does the media prefer RZLT or AARD?

Do insiders & institutionals hold more shares of RZLT or AARD?

Is RZLT or AARD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD vs. The Competition

Aardvark Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools